Factor VIII
Altuviiio Highly Effective Against Bleeding in Children With Severe Hemophilia A
The phase 3 XTEND-Kids study evaluating antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein (Altuviiio, ...
JUNE 26, 2023
FDA Approves First Hemophilia A With Inhibitors Treatment in 20 Years
Genentech's Hemlibra is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
NOVEMBER 17, 2017
New Indication Granted for Adynovate
Adynovate can now be used for children younger than 12 years of age.
DECEMBER 27, 2016
Load more